Better Therapeutics (BTTX) Stock Price, News & Analysis

Company Overview

Better Therapeutics, Inc. was a digital therapeutics company focused on developing prescription software treatments for cardiometabolic diseases. Its platform used cognitive behavioral therapy and other behavior-change techniques to help patients improve habits related to conditions such as type 2 diabetes and cardiovascular disease.

The company’s lead product, AspyreRx, formerly known as BT-001, was a prescription digital therapeutic designed to support adults with type 2 diabetes. Delivered through a software application, the treatment aimed to help patients make sustainable changes involving nutrition, physical activity and other lifestyle behaviors. AspyreRx received clearance from the U.S. Food and Drug Administration in 2023.

Better Therapeutics was headquartered in the United States and focused primarily on the U.S. healthcare market, working within the prescription digital therapeutics and virtual-care sectors. The company subsequently announced plans to wind down operations and pursue liquidation, and its business activities may no longer be ongoing. Information about its current leadership and operating status is therefore limited.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 10,036 shs
• Market Capitalization: $4 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 10/05/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Health services
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:BTTX
• CIK: 1832415
• Web: mcacquisition.com
• Phone: 415-887-2311
• Fax: N/A
• Employees: 40
• Year Founded: 2015

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 40,580,000
• Free Float: 24,233,000
• Market Cap: $4 thousand
• Optionable: No Data
• Beta: 0.85